Andrew Obenshain

Andrew Obenshain serves as the Chief Executive Officer of a biotech company, a role he has held since 2021. He is deeply committed to enhancing the lives of patients and their families through the development of therapies for rare diseases. Obenshain joined the company in 2016 as the head of Europe and later served as President of Severe Genetic Diseases. His career in the biotech industry includes significant positions at Shire, where he was the general manager for France and Benelux, managing a portfolio of seven rare disease products. He also spent eight years at Genzyme and Sanofi, engaging in business development, marketing, and global commercial operations. Obenshain began his career as a consultant and venture capital investor focusing on small biotech firms. He holds an MBA from Northwestern University’s Kellogg School of Management and a B.A. in genetics, cell, and developmental biology from Dartmouth College. Notably, he has an identical twin.